Radotinib induces CD11b+Annexin V+ cells in BMCs from patients with AML.

Cells were incubated with various concentrations of radotinib for 72 h, harvested and immunostained with anti-human antibodies against CD11b and Annexin V. (A) The CD11b+Annexin V+ cells in AML-1, AML-2 and AML-4. (B) Data show the fold-change of the number of CD11b+Annexin V+ cells compared to control conditions in AML-1, AML-2, and AML-4. (C) The expression of Annexin V and CD11b in cells treated with 100 μM radotinib was monitored by FlowSight analysis (Patients: AML-1 and AML-4). Data represent the mean ± SEM. Statistically significant differences from the DMSO-treated control (*) are denoted as follows. **: P < 0.01; ***: P < 0.001. BF, bright field.